Anteris Technologies Global Corp - Asset Resilience Ratio

Latest as of December 2024: 33.27%

Anteris Technologies Global Corp (AVR) has an Asset Resilience Ratio of 33.27% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Anteris Technologies Global Corp debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$43.38 Million
≈ $30.69 Million USD Cash + Short-term Investments

Total Assets

AU$130.39 Million
≈ $92.26 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Anteris Technologies Global Corp's Asset Resilience Ratio has changed over time. See AVR book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Anteris Technologies Global Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Anteris Technologies Global Corp (AVR) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$43.38 Million 33.27%
Total Liquid Assets AU$43.38 Million 33.27%

Asset Resilience Insights

  • Very High Liquidity: Anteris Technologies Global Corp maintains exceptional liquid asset reserves at 33.27% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Anteris Technologies Global Corp Industry Peers by Asset Resilience Ratio

Compare Anteris Technologies Global Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Sino Medical Sciences Technology In
SHG:688108
Medical Devices 0.66%
Polynovo Ltd
AU:PNV
Medical Devices 5.46%
Beijing Succeeder Technology Inc
SHG:688338
Medical Devices 28.66%
Tellgen Corp
SHE:300642
Medical Devices 8.60%
Respiri Ltd
AU:RSH
Medical Devices 0.46%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.39%
Duearity AB
ST:DEAR
Medical Devices 145.62%

Annual Asset Resilience Ratio for Anteris Technologies Global Corp (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Anteris Technologies Global Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 33.27% AU$43.38 Million
≈ $30.69 Million
AU$130.39 Million
≈ $92.26 Million
+32.89pp
2022-12-31 0.38% AU$88.76K
≈ $62.80K
AU$23.48 Million
≈ $16.61 Million
+0.08pp
2021-12-31 0.30% AU$88.56K
≈ $62.66K
AU$29.48 Million
≈ $20.86 Million
-0.58pp
2020-12-31 0.88% AU$111.00K
≈ $78.54K
AU$12.65 Million
≈ $8.95 Million
-26.57pp
2019-12-31 27.44% AU$7.14 Million
≈ $5.05 Million
AU$26.00 Million
≈ $18.40 Million
+10.46pp
2018-12-31 16.99% AU$5.41 Million
≈ $3.83 Million
AU$31.86 Million
≈ $22.54 Million
-1.02pp
2017-12-31 18.01% AU$5.11 Million
≈ $3.61 Million
AU$28.37 Million
≈ $20.07 Million
--
2016-12-31 0.00% AU$0.00
≈ $0.00
AU$28.58 Million
≈ $20.22 Million
--
2015-12-31 0.00% AU$0.00
≈ $0.00
AU$26.78 Million
≈ $18.95 Million
--
2010-12-31 1.98% AU$291.36K
≈ $206.16K
AU$14.75 Million
≈ $10.44 Million
--
pp = percentage points

About Anteris Technologies Global Corp

AU:AVR Australia Medical Devices
Market Cap
$558.50 Million
AU$789.33 Million AUD
Market Cap Rank
#11961 Global
#303 in Australia
Share Price
AU$8.15
Change (1 day)
+5.84%
52-Week Range
AU$4.69 - AU$9.75
All Time High
AU$83.50
About

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calci… Read more